Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study

af Braess, Jan, Amler, Susanne, Kreuzer, Karl-Anton, Spiekermann, Karsten, Lindemann, Hans Walter, Lengfelder, Eva, Graeven, Ullrich, Staib, Peter, Ludwig, Wolf-Dieter, Biersack, Harald, Ko, Yon-Dschun, Uppenkamp, Michael J., De Wit, Maike, Korsten, Stefan, Peceny, Rudolf, Gaska, Tobias, Schiel, Xaver, Behringer, Dirk M., Kiehl, Michael G., Zinngrebe, Bettina, Meckenstock, Gerald, Roemer, Eva, Medgenberg, Dirk, Spaeth-Schwalbe, Ernst, Massenkeil, Gero, Hindahl, Heidrun, Schwerdtfeger, Rainer, Trenn, Guido, Sauerland, Cristina, Koch, Raphael, Lablans, Martin, Faldum, Andreas, Görlich, Dennis, Bohlander, Stefan K., Schneider, Stephanie, Dufour, Annika, Buske, Christian, Fiegl, Michael, Subklewe, Marion, Braess, Birgit, Unterhalt, Michael, Baumgartner, Anja, Wörmann, Bernhard, Beelen, Dietrich, Hiddemann, Wolfgang
Udgivet i Leukemia (2018)